KDI Capital Partners LLC decreased its stake in MEDNAX Inc (NYSE:MD) by 51.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 79,147 shares of the company’s stock after selling 82,675 shares during the period. MEDNAX accounts for 1.7% of KDI Capital Partners LLC’s portfolio, making the stock its 27th biggest position. KDI Capital Partners LLC’s holdings in MEDNAX were worth $4,230,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. acquired a new position in shares of MEDNAX in the 3rd quarter valued at $103,000. Delta Capital Management LLC acquired a new stake in MEDNAX during the 4th quarter worth $227,000. Brown Advisory Inc. acquired a new stake in MEDNAX during the 4th quarter worth $231,000. YHB Investment Advisors Inc. acquired a new stake in MEDNAX during the 4th quarter worth $235,000. Finally, Shelton Capital Management acquired a new stake in MEDNAX during the 4th quarter worth $245,000. Institutional investors and hedge funds own 95.12% of the company’s stock.
MD has been the subject of a number of recent research reports. KeyCorp set a $51.00 price target on shares of MEDNAX and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Stephens set a $62.00 price target on shares of MEDNAX and gave the stock a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research upgraded shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a research note on Tuesday, January 23rd. SunTrust Banks set a $55.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research note on Thursday, December 21st. Finally, Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research note on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $54.92.
MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.87 EPS for the quarter, topping the Zacks’ consensus estimate of $0.83 by $0.04. The company had revenue of $910.82 million during the quarter, compared to the consensus estimate of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. MEDNAX’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 EPS. sell-side analysts expect that MEDNAX Inc will post 4.03 earnings per share for the current year.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the transaction, the insider now owns 35,569 shares in the company, valued at approximately $1,834,649.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.40% of the stock is currently owned by corporate insiders.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.